Therapy Detail

Therapy Name MSC2490484A
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MSC2490484A M3814|M-3814 DNA_PK Inhibitor 5 MSC2490484A is a DNA-dependent protein kinase (DNA-PK) inhibitor that blocks DNA damage repair, which may lead to antitumor activity (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor no benefit MSC2490484A Phase I Actionable In a Phase I trial, MSC2490484A (M3814) demonstrated safety, but limited clinical activity, in patients with solid tumors (J Clin Oncol 35, 2017 (suppl; abstr 2556)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02516813 Phase I MSC2490484A Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Active, not recruiting
NCT03116971 Phase Ib/II Cisplatin + Etoposide + MSC2490484A MSC2490484A Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) Terminated